Forward Pharma KRASG12C compound 19

Forward Pharma KRASG12C compound 19: sourced facts only. name: "This design strategy yielded compounds 19 and 20, which displayed sub-nanomolar cellular potency against KRASG12C-driven cell proliferation (NCI-H358, IC50 = 0.5 nM for both) and crucially retained potent activity against the clinically relevant KRAS G12C-R68S resistance variant (Ba/F3, IC50 = 29.8 nM and 5.4 nM, respectively)." [PMID:41187566]; target: "This design strategy yielded compounds 19 and 20, which displayed sub-nanomolar cellular potency against KRASG12C-driven cell proliferation (NCI-H358, IC50 = 0.5 nM for both) and crucially retained potent activity against the clinically relevant KRAS G12C-R68S resistance variant (Ba/F3, IC50 = 29.8 nM and 5.4 nM, respectively)." [PMID:41187566]; developer: "Forward Pharmaceuticals Co. Ltd., Shenzhen, 518063, Guangdong Province, PR China." [PMID:41187566]; stage: "Pharmacokinetic optimization achieved high oral bioavailability (F = 60.7 % for 19, F = 40.8 % for 20) with sustained tumor exposure, enabling near-complete tumor regression (TGI = 103 %) in SW837 rectal xenografts at 30 mg/kg QD without observable toxicity." [PMID:41187566]